By-health(SZ:300146)2023-08-04 16:00Financial Performance - The company reported a total revenue of 1.2 billion yuan for the first half of 2023, representing a year-on-year increase of 15%[1]. - The company's operating revenue for the reporting period reached CNY 5,596,022,896.78, representing a 32.58% increase compared to CNY 4,220,918,971.74 in the same period last year[30]. - The net profit attributable to shareholders was CNY 1,545,404,273.01, marking a 47.41% increase from CNY 1,048,279,574.14 in the previous year[30]. - The company has set a performance guidance of 1.5 billion yuan in revenue for the second half of 2023, reflecting a 25% growth target compared to the same period last year[1]. - The basic earnings per share rose to CNY 0.91, up 46.77% from CNY 0.62 in the previous year[30]. - The company's total revenue from the domestic online channel was ¥934,548,535.46, with a gross margin of 75.87%, an increase of 6.89 percentage points year-on-year[60]. - The company achieved a revenue of 5.596 billion yuan, representing a year-on-year growth of 32.58%, and a net profit of 1.545 billion yuan, up 47.41% year-on-year[89]. User Growth and Market Expansion - User data showed an increase in active users by 20% year-on-year, reaching 5 million active users[1]. - Market expansion efforts include entering two new international markets, aiming for a 10% increase in overseas sales by the end of 2024[1]. - The company is actively pursuing strategic acquisitions, with a target of completing at least one acquisition by the end of 2023 to enhance its product portfolio[1]. - The company’s overseas business, LSG, achieved revenue of 536 million yuan, a year-on-year increase of 42.26% (1.14 million AUD, up 41.11%)[90]. - The company is expanding its market presence in Southeast Asia by establishing overseas subsidiaries and collaborating with distributors[96]. Research and Development - The company has allocated 200 million yuan for R&D in new technologies and product innovations for the upcoming fiscal year[1]. - The company has a total of 370 patents in China as of June 30, 2023, with 34 new patents added during the reporting period[81]. - The company has invested in R&D partnerships with leading research institutions, resulting in 379 patents, including 103 invention patents related to raw materials and formulations[77]. - The company is committed to research and development, as evidenced by the numerous patents filed in 2023[83]. - The company plans to continue its research and development efforts for new products and technologies, as discussed in various meetings[139]. Quality Control and Risk Management - The gross profit margin for the same period was 45%, slightly up from 43% in the previous year, indicating improved cost management[1]. - The company emphasizes a commitment to quality control, with an investment of 50 million yuan in quality management systems and third-party inspections[1]. - The company has identified potential risks related to raw material price fluctuations, which could impact gross margins, and is implementing strategies to mitigate these risks[1]. - The gross profit margin for the main business improved to 70.69%, an increase of 0.98 percentage points year-on-year[101]. - The company emphasizes a rigorous quality control system, having obtained ISO 9001:2015 certification and other quality management recognitions[78]. Sales and Distribution - The online sales revenue for the first half of 2023 reached ¥1,221,831,986.07, with a gross margin of 78.26%, up from 75.30% in the same period of 2022[64]. - The total number of distributors decreased from 1,039 at the end of 2022 to 944 at the end of the reporting period, a reduction of 95[62]. - The company has established a comprehensive sales system covering offline retail channels, with significant sales on e-commerce platforms like Alibaba and JD, leading the industry in sales volume[79]. - The company reported a total sales amount of ¥1,168,603,583.22 from its top five customers, accounting for 20.88% of total sales for the half-year[62]. Corporate Social Responsibility - The company emphasizes corporate social responsibility and adheres to legal operations while supporting local economic development[157]. - The company has engaged in various social welfare activities, including the "1+1+Hope Project," which has built 18 hope primary schools since 2005[166]. - The company donated over 10 million RMB to UNICEF for early childhood nutrition projects from 2020 to 2022, supporting infant feeding practices and policy environment[167]. - The company has established a "Scientific Nutrition Special Fund" in collaboration with the Guangdong Zhong Nanshan Medical Foundation to promote community health initiatives[169]. - The company has actively participated in the "Guangdong Poverty Alleviation Day" by donating 1 million RMB to support rural revitalization efforts[170]. Investor Relations and Governance - The company held its annual general meeting on April 10, 2023, with a participation rate of 59.71%[143]. - The company plans not to distribute cash dividends or issue bonus shares for the semi-annual period[146]. - The company conducted multiple investor communication activities, including on-site and remote meetings, with various institutional investors throughout January to June 2023[139][140][141]. - The company is committed to maintaining transparency and open communication with investors regarding its performance and future outlook[139][140]. Environmental Management - The company has implemented a comprehensive environmental management system and has passed certifications for clean production and energy management[156]. - The company has not been penalized for environmental issues during the reporting period and is not classified as a key pollutant discharge unit[156]. - The company has focused on sustainable development by implementing energy-saving measures and reducing greenhouse gas emissions[165]. Legal Matters - The company is involved in a lawsuit with Shenzhen Beitai Health Measurement Analysis Technology Co., Ltd., with a disputed amount of 237.42 million yuan, which has been dismissed in the first instance[177]. - There are other minor lawsuits totaling 17.14 million yuan, with 3.76 million yuan already concluded and the remaining 13.37 million yuan still pending[178]. - The company has not reported any significant related party transactions during the reporting period[179].